Table 2 Receptor-Binding Profiles for SLV313 and the Reference Compounds Aripiprazole, Clozapine, Haloperidol, Risperidone, Ziprasidone, and Olanzapine
Compound | D 2 | D 3 | D 4 | 5-HT 1A | 5-HT 2A | 5-HT 2B | 5-HT 2C | 5-HT 4 | 5-HT 6 | 5-HT 7 | 5-HT 3 | 5-HT UP | M 1 | M 4 | α 1 | α 2 | H 1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SLV313 | 8.4±0.2 | 8.4±0.2 | 8.0±0.2 | 9.1±0.1 | 6.6±0.2 | 7.9±0.1 | Inactive | Inactive | Inactive | 7.2±0.1 | Inactive | Inactive | Inactive | Inactive | 6.3±0.2 | Inactive | Inactive |
Aripiprazole | 8.3±0.2 | 8.4±0.2 | 7.0±0.1 | 8.1±0.1 | 7.8±0.2 | 8.9±0.3 | 7.3±0.2 | Inactive | 6.7±0.1 | 7.2±0.2 | 6.3±0.2 | 7.5±0.1 | Inactive | Inactive | 7.0±0.2 | Inactive | 7.0±0.1 |
Clozapine | 6.9±0.1 | 7.0±0.2 | 7.3±0.1 | 7.0±0.1 | 8.3±0.2 | 8.5±0.1 | 8.1±0.1 | Inactive | 8.1±0.1 | 7.7±0.4 | 6.4±0.1 | Inactive | 8.2±0.3 | 7.9±0.1 | 8.0±0.2 | 7.1±0.2 | 8.1±0.2 |
Haloperidol | 8.3±0.2 | 8.8±0.2 | 8.2±0.1 | Inactive | 7.0±0.2 | Inactive | Inactive | Inactive | Inactive | 6.5±0.1 | Inactive | Inactive | Inactive | Inactive | 7.8±0.2 | Inactive | 6.4±0.2 |
Olanzapine | 7.7±0.1 | 7.7±0.3 | 7.7±0.3 | Inactive | 8.8±0.1 | 8.2±0.0 | 8.3±0.2 | Inactive | 8.1±0.1 | 7.1±0.1 | 6.7±0.1 | Inactive | 8.0±0.1 | 7.9±0.2 | 7.6±0.3 | 6.5±0.1 | 8.2±0.2 |
Risperidone | 8.2±0.1 | 8.0±0.1 | 8.0±0.1 | 6.6±0.1 | 9.0±0.1 | 7.7±0.1 | 7.9±0.1 | Inactive | Inactive | 9.0±0.2 | Inactive | Inactive | Inactive | Inactive | 8.8±0.2 | 8.1±0.1 | 8.1±0.3 |
Ziprasidone | 7.9±0.2 | 8.2±0.2 | 7.3±0.2 | 8.8±0.1 | 9.2±0.1 | 8.8±0.1 | 8.9±0.2 | Inactive | 7.2±0.1 | 8.3±0.1 | 6.4±0.1 | 7.1±0.2 | Inactive | Inactive | 8.1±0.1 | 6.3±0.1 | 7.8±0.1 |
